122 related articles for article (PubMed ID: 16952108)
1. Allergic contact dermatitis caused by latanoprost ophthalmic solution.
Lai CH; Lai IC; Chi CC
Eur J Ophthalmol; 2006; 16(4):627-9. PubMed ID: 16952108
[TBL] [Abstract][Full Text] [Related]
2. Eyelid hypertrichosis associated with latanoprost is reversible.
O'Toole L; Cahill M; O'Brien C
Eur J Ophthalmol; 2001; 11(4):377-9. PubMed ID: 11820311
[TBL] [Abstract][Full Text] [Related]
3. Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops.
Pérez-Rodríguez E; González-Pérez R; Poza P; Feliciano L; López-Correcher B; Matheu V
Contact Dermatitis; 2008 Jun; 58(6):370-1. PubMed ID: 18503690
[No Abstract] [Full Text] [Related]
4. Allergic contact dermatitis to latanoprost.
Jerstad KM; Warshaw E
Am J Contact Dermat; 2002 Mar; 13(1):39-41. PubMed ID: 11887105
[TBL] [Abstract][Full Text] [Related]
5. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution.
Sakata R; Shirato S; Miyata K; Aihara M
Eye (Lond); 2014 Dec; 28(12):1446-51. PubMed ID: 25233818
[TBL] [Abstract][Full Text] [Related]
6. Increased eyelid pigmentation associated with use of latanoprost.
Kook MS; Lee K
Am J Ophthalmol; 2000 Jun; 129(6):804-6. PubMed ID: 10926995
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus dermatitis in patients using latanoprost.
Morales J; Shihab ZM; Brown SM; Hodges MR
Am J Ophthalmol; 2001 Jul; 132(1):114-6. PubMed ID: 11438068
[TBL] [Abstract][Full Text] [Related]
8. Allergic contact dermatitis caused by topical eye drops.
Spaeth GL
Am J Ophthalmol; 2006 Oct; 142(4):706. PubMed ID: 17011880
[No Abstract] [Full Text] [Related]
9. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
Inoue K; Shiokawa M; Wakakura M; Tomita G
J Glaucoma; 2013; 22(8):626-31. PubMed ID: 22936280
[TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
[TBL] [Abstract][Full Text] [Related]
11. Eyelash hypertrichosis induced by topical latanoprost: 6-month follow-up study.
Stecchi G; Saccucci S; Molinari S; De Gregorio F
Acta Ophthalmol Scand Suppl; 2002; 236():56-7. PubMed ID: 12390146
[No Abstract] [Full Text] [Related]
12. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
[TBL] [Abstract][Full Text] [Related]
14. Latanoprost-induced prostaglandin-associated periorbitopathy.
Tan J; Berke S
Optom Vis Sci; 2013 Sep; 90(9):e245-7; discussion 1029. PubMed ID: 23912967
[TBL] [Abstract][Full Text] [Related]
15. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
[TBL] [Abstract][Full Text] [Related]
17. Ocular complications of latanoprost in uveitic glaucoma: three case reports.
Saccà S; Pascotto A; Siniscalchi C; Rolando M
J Ocul Pharmacol Ther; 2001 Apr; 17(2):107-13. PubMed ID: 11324978
[TBL] [Abstract][Full Text] [Related]
18. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
19. Heart block following topical latanoprost treatment.
De Smit E; Theodorou M; Hildebrand GD; Bloom P
BMJ Case Rep; 2011 Oct; 2011():. PubMed ID: 22679164
[TBL] [Abstract][Full Text] [Related]
20. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
